Abstract
This spotlight highlights a novel multimodal risk stratification model for patients with locally advanced non–small cell lung cancer undergoing chemoradiation, integrating mid-treatment ctDNA kinetics with radiomic features from baseline imaging. The study by Moding and colleagues provides compelling proof-of-concept data for real-time response-adaptive therapy, though further work is needed to address implementation barriers and standardize these biomarkers for clinical use.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1534-1536 |
| Number of pages | 3 |
| Journal | Cancer discovery |
| Volume | 15 |
| Issue number | 8 |
| DOIs | |
| State | Published - 2025 |
ASJC Scopus subject areas
- Oncology
Fingerprint
Dive into the research topics of 'In the Spotlight Toward Response-Adaptive Therapy in Locally Advanced NSCLC: Integrating ctDNA and Radiomics for Risk Stratification'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS